Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest update is out from Vaxart ( (VXRT) ).
On August 27, 2025, Vaxart received a decision from the Nasdaq Hearings Panel allowing the company to continue its listing on Nasdaq, contingent upon meeting specific conditions including a reverse stock split by October 17, 2025. This decision follows a period of non-compliance with Nasdaq’s minimum bid price requirement, and the company is actively engaging with stockholders to secure their support for the necessary actions to maintain its listing, which is critical for its future success in the competitive vaccine industry.
The most recent analyst rating on (VXRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Vaxart stock, see the VXRT Stock Forecast page.
Spark’s Take on VXRT Stock
According to Spark, TipRanks’ AI Analyst, VXRT is a Neutral.
Vaxart’s overall score is primarily influenced by its strong revenue growth and promising vaccine developments, which are offset by significant profitability challenges and technical bearishness. The negative P/E ratio and NASDAQ listing issues further weigh on the stock’s attractiveness.
To see Spark’s full report on VXRT stock, click here.
More about Vaxart
Vaxart is a clinical-stage biotechnology company focused on developing oral recombinant vaccines using its proprietary delivery platform. The company’s vaccines are designed to be administered as pills, which do not require refrigeration and eliminate the risk of needle-stick injury. Vaxart’s development programs include vaccines for coronavirus, norovirus, influenza, and a therapeutic vaccine for HPV, marking its first foray into immune-oncology.
Average Trading Volume: 4,540,877
Technical Sentiment Signal: Sell
Current Market Cap: $82.41M
See more data about VXRT stock on TipRanks’ Stock Analysis page.